Fusion Antibodies (LSE:FAB) Dividend Payout Ratio : 0.00 (As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies Dividend Payout Ratio?

Fusion Antibodies's dividend payout ratio for the months ended in Sep. 2023 was 0.00.

The historical rank and industry rank for Fusion Antibodies's Dividend Payout Ratio or its related term are showing as below:

LSE:FAB's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.415
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-05-01), the Dividend Yield % of Fusion Antibodies is 0.00%.

Fusion Antibodies's Dividends per Share for the months ended in Sep. 2023 was £0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Fusion Antibodies Dividend Payout Ratio Historical Data

The historical data trend for Fusion Antibodies's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies Dividend Payout Ratio Chart

Fusion Antibodies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Dividend Payout Ratio

Get a 7-Day Free Trial

Fusion Antibodies Semi-Annual Data
	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Dividend Payout Ratio	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of Fusion Antibodies's Dividend Payout Ratio

For the Biotechnology subindustry, Fusion Antibodies's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fusion Antibodies's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Antibodies's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Fusion Antibodies's Dividend Payout Ratio falls into.

Fusion Antibodies Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Fusion Antibodies's Dividend Payout Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Mar. 2023 )	/	EPS without NRI (A: Mar. 2023 )
	=	0	/	-0.1
	=	N/A

Fusion Antibodies's Dividend Payout Ratio for the quarter that ended in Sep. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2023 )	/	EPS without NRI (Q: Sep. 2023 )
	=	0	/	-0.029
	=	N/A

Fusion Antibodies (LSE:FAB) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Fusion Antibodies Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusion Antibodies (LSE:FAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL

Website

https://www.fusionantibodies.com

Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies (LSE:FAB) Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor • 10-21-2022